Skye Bioscience (SKYE) Proxy filing summary

Executive summary

• Received Nasdaq notification for non-compliance with minimum $2.5M stockholders' equity as of June 30, 2026, with equity reported at ($497,307).

• Common stock continues trading on Nasdaq; company has 45 days to submit a compliance plan, with potential extension up to 180 days.

• Evaluating alternative actions to regain compliance; no assurance of success.

• Proposed acquisition of Redx Pharma Limited announced, with proxy statement to be filed for shareholder approval.

• Forward-looking statements highlight risks related to compliance, transaction completion, integration, and regulatory approvals.

Voting matters and shareholder proposals

• Proxy statement to be filed for shareholder vote on the proposed acquisition of Redx Pharma Limited.

• Shareholders urged to review proxy materials for important information regarding the transaction.

Board of directors and corporate governance

• Directors and executive officers may participate in proxy solicitation for the Redx acquisition.

• Information on directors’ and officers’ interests available in recent SEC filings and will be updated in the proxy statement.